1 |
孙路遥, 尹梦媛, 谢克平, 等. 肿瘤相关成纤维细胞在胰腺癌发生发展中的研究进展 [J].肿瘤学杂志, 2021, 27(2): 95-104.
|
2 |
Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win [J]. World J Gastroenterol, 2021, 27(35): 5851-5889.
|
3 |
吕伟, 刘一娇, 邬丹莲, 等. 白蛋白结合型紫杉醇用于多种实体肿瘤治疗的卫生技术评估 [J/OL]. 今日药学: 1-15.
|
4 |
毛雨秋, 陈良峰, 韩菲菲. 尼妥珠单抗联合GS化疗治疗晚期胰腺癌患者临床研究 [J]. 中国合理用药探索, 2019, 16(10): 29-31.
|
5 |
祁娟, 郭伟华, 段仁慧. 白蛋白结合型紫杉醇联合吉西他滨与吉西他滨单药治疗晚期胰腺癌的疗效及安全性 [J]. 新疆医学, 2022, 52(10): 1165-1167+1178.
|
6 |
王尧, 钟国成, 李迎春, 等. 尼妥珠单抗联合盐酸吉西他滨治疗高表达表皮生长因子受体中晚期胰腺癌患者的临床研究 [J]. 成都医学院学报, 2020, 15(5): 615-618.
|
7 |
韩春, 叶斯斯, 李娟, 等. 尼妥珠单抗联合吉西他滨一线治疗晚期胰腺癌的疗效观察 [J].解放军医学院学报, 2021, 42(6): 596-600+614.
|
8 |
Han SY, Kim DU, Seol YM, et al. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer [J]. World J Clin Cases, 2020, 8(17): 3718-3729.
|
9 |
Zuzčák M, Trnka J. Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review) [J]. Int J Oncol, 2022, 61(2): 93.
|
10 |
Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors [J]. Nat Rev Gastroenterol Hepatol, 2021, 18(7): 493-502.
|
11 |
李惠, 曹永春, 于拥军, 等. FNDC5/Irisin、NEDD9在胰腺癌组织中的表达及给予白蛋白结合型紫杉醇联合吉西他滨治疗的预后观察 [J]. 临床医学工程, 2022, 29(11): 1493-1494.
|
12 |
张伟, 姜卫, 武凯龙, 等. 同步放化疗和尼妥珠单抗联合放疗治疗老年晚期鼻咽癌的疗效对比分析 [J]. 中国肿瘤临床与康复, 2022, 29(4): 425-427.
|
13 |
Tian Z, Yao W. Albumin-bound paclitaxel: worthy of further study in sarcomas [J]. Front Oncol, 2022, 12: 815900.
|
14 |
Sato T, Okazaki M, Sano J, et al. Binding affinities of paclitaxel and docetaxel for generic and nanoparticle albumin-bound paclitaxel-derived albumin from human serum [J]. Biomed Rep, 2021, 14(4): 35.
|
15 |
Lv ZD, Song HM, Niu ZH, et al. Efficacy and safety of albumin-bound paclitaxel compared to docetaxel as neoadjuvant chemotherapy for HER2-negative breast cancer [J]. Front Oncol, 2022, 11: 760655.
|
16 |
Abourehab MAS, Alqahtani AM, Youssif BGM, et al. Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism [J]. Molecules, 2021, 26(21): 6677.
|
17 |
Yuan Y, Chen J, Fang M,et al. Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials [J]. Front Oncol, 2022, 12: 994726.
|
18 |
潘琦, 忻笑. 白蛋白结合型紫杉醇治疗晚期胰腺癌患者的护理体会 [J]. 上海护理, 2020, 20(9): 53-55.
|
19 |
马艳荣, 赵莉, 王永增, 等. 尼妥珠单抗联合吉西他滨和替吉奥方案用于晚期胰腺癌的疗效观察及对癌组织中E钙黏蛋白和β-连环蛋白表达的影响 [J]. 中国医药, 2021, 16(10): 1480-1484.
|